When the team behind Arcutis Biotherapeutics were putting the company together in 2016, it seemed like the majority of investors wanted the company to be built out in one of two places — San Francisco or San Diego. But Frank Watanabe, the man who would become the CEO of the company, had other ideas. “He…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
